Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomics and machine learning-guided ceftazidime/avibactam therapy for CRO infections
ChiCTR2500109804Phase 4Not yet recruiting
- Sponsor
- Wuxi People's Hospital
- Start
- Sep 2025
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ceftazidime + avibactam in Gram-negative bacterial infection (2 arms), sponsored by Wuxi People's Hospital. Primary endpoint: 30-day mortality rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
ceftazidime + avibactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on ChiCTR2500109804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109804.